Gerben Menschaert: Kick-off of the European BRECISE Project!
Gerben Menschaert, Co-founder of OHMX bio, posted on LinkedIn:
“Kick-off of the European BRECISE Project!
We’re excited to kick off this ambitious initiative in Madrid! It’s great to be doing this alongside one of our first collaborators, Ralf Hoffmann (Philips Eindhoven), and 30 esteemed academic and industry partners from across Europe.
The BRECISE project is dedicated to advancing cancer biomarker validation and precision medicine focussing on prostate and bladder cancer.
Today, I had the opportunity to present OHMX bio’s role in the project—leading the clinical next-generation DNA and RNA sequencing analysis of a diverse range of cancer samples. We’ll be leveraging cutting-edge technologies, including Oxford Nanopore Technologies, Element Biosciences, and Illumina to drive innovation in this space.
Looking forward to this five-year journey and the impact it will have on patients and clinicians!
See press release.”
Read more about Precision Medicine on oncodaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023